HRGN — Harvard Apparatus Regenerative Technology Share Price
0.000.00%
Last trade - 00:00- $41.81m
- $42.04m
- $0.10m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 214.32 | ||
| Price to Tang. Book | 214.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 234.41 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4642.29% | ||
| Return on Equity | n/a | ||
| Operating Margin | -5077.5% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 0.1 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company. It uses the patient’s own stem cells grown on a porous plastic tubular scaffold to regenerate the esophagus after it has been removed due to cancer, trauma, or birth defects. The Company is targeting the conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy and birth defects. Its additional product candidates in its development pipeline are targeted at the reconstruction of the colon and uterus wound repair. Its product candidate includes Cellspan Esophageal Implant, and Cellspan Bronchial Implants. It is developing Cellspan Esophageal Implant for the treatment of esophageal atresia. Esophageal atresia is a birth disorder of the digestive system in which the esophagus does not develop properly. Cellspan Bronchial Implants enables the surgeon to preserve the lung and repair the bronchus through various surgical resection.
Directors
- David Green CHM (57)
- Hong Yu PRE (46)
- Jason Jing Chen VCH
- Peter Pellegrino CFO (46)
- Harout DerSimonian CSO
- Ting Li DRC
- Herman Sanchez DRC
- James Shmerling DRC (63)
- Junli He IND (47)
- Thomas Robinson IND
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- May 3rd, 2012
- Public Since
- October 14th, 2013
- No. of Shareholders
- 140
- No. of Employees
- 10
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 14,315,091
- Address
- 84 October Hill Road, Suite 11, HOLLISTON, 01746
- Web
- https://www.biostage.com/
- Phone
- +1 7742337300
- Auditors
- Marcum LLP
Upcoming Events for HRGN
Q2 2024 Harvard Apparatus Regenerative Technology Inc Earnings Release
Q3 2024 Harvard Apparatus Regenerative Technology Inc Earnings Release
Similar to HRGN
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
What is the Harvard Apparatus Regenerative Technology share price?
As of Today at 21:04 UTC, shares in Harvard Apparatus Regenerative Technology are trading at $2.62. This share price information is delayed by 15 minutes.
How has the Harvard Apparatus Regenerative Technology share price performed this year?
Shares in Harvard Apparatus Regenerative Technology last closed at $2.62 and the price had moved by -34.5% over the past 365 days. In terms of relative price strength the Harvard Apparatus Regenerative Technology share price has underperformed the S&P500 Index by -45.03% over the past year.
What are the analyst and broker recommendations for Harvard Apparatus Regenerative Technology?
There is no consensus recommendation for this security.
What is the Harvard Apparatus Regenerative Technology dividend yield?
Harvard Apparatus Regenerative Technology does not currently pay a dividend.
Does Harvard Apparatus Regenerative Technology pay a dividend?
Harvard Apparatus Regenerative Technology does not currently pay a dividend.
When does Harvard Apparatus Regenerative Technology next pay dividends?
Harvard Apparatus Regenerative Technology does not currently pay a dividend.
How do I buy Harvard Apparatus Regenerative Technology shares?
To buy shares in Harvard Apparatus Regenerative Technology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Harvard Apparatus Regenerative Technology?
As of the previous close price of $2.62, shares in Harvard Apparatus Regenerative Technology had a market capitalisation of $37.51m.
Where are Harvard Apparatus Regenerative Technology shares listed?
Here are the trading details for Harvard Apparatus Regenerative Technology:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: HRGN
What kind of share is Harvard Apparatus Regenerative Technology?
Based on an overall assessment of its quality, value and momentum Harvard Apparatus Regenerative Technology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Harvard Apparatus Regenerative Technology share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Harvard Apparatus Regenerative Technology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Harvard Apparatus Regenerative Technology. Over the past six months, its share price has underperformed the S&P500 Index by -52.55%.
As of the last closing price of $2.62, shares in Harvard Apparatus Regenerative Technology were trading -40.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Harvard Apparatus Regenerative Technology PE Ratio?
The Harvard Apparatus Regenerative Technology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.62.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Harvard Apparatus Regenerative Technology?
Harvard Apparatus Regenerative Technology's management team is headed by:
- David Green - CHM
- Hong Yu - PRE
- Jason Jing Chen - VCH
- Peter Pellegrino - CFO
- Harout DerSimonian - CSO
- Ting Li - DRC
- Herman Sanchez - DRC
- James Shmerling - DRC
- Junli He - IND
- Thomas Robinson - IND